The Cigna Group (CI) emerges as one of the top recommendations within health insurance stocks in 2025. The Group has presented its Q4 2024 earnings, delivering a strong outlook for 2025, and a climbing dividend. Despite cost challenges, Q4 earnings highlighted continued revenue growth, and sell-offs including those by Sumitomo Mitsui DS Asset and Choreo LLC, notable investments have been made by firms like Financial Life Planners and abrdn plc. Piper Sandler reaffirmed its overweight rating for CI, appreciating their 39% return over five years. The longevity and value of CI stock is being touted by industry analysts, with Larry Robbins and Lee Cooperman remaining bullish. Interestingly, CI faced a downward revision in price targets by multiple firms including UBS Group, Morgan Stanley, Oppenheimer, and Wells Fargo and Company. Despite lower-than-expected Q4 earnings, CI plans to boost their dividend to $1.51 per share. Downgrades and price cuts were seen from Bernstein SocGen Group and Truist. CI launched customer-centric initiatives, reputed for its 89% institutional ownership, and despite some weak fundamentals, the company remains attractive for its safe-dividend status.
The Cigna Group CI News Analytics from Mon, 14 Oct 2024 07:00:00 GMT to Sat, 08 Feb 2025 20:54:38 GMT -
Rating 2
- Innovation -4
- Information 6
- Rumor -3
